A straw-colored substance in blood called plasma could easily be one of the most important things in medicine. Also termed as protein-salt solution, it is a mix of red and white blood cells, platelets and over a hundred different protein strains and is separated, or extracted using fractionation and these derivatives are used in different clinical applications, treatment of diseases, therefore, fueling the growth of the Global Blood Plasma Products Market.
Still derived from blood donors, it is the new and better-developed fractionation procedures that help develop and preserve blood plasma derivatives from those donors for longer. This is so that it can then be processed for use with the treatment of issues like HIV, hepatitis, and hemophilia HIV, hepatitis, and hemophilia creating a demand in the global blood plasma derivatives market. Both factors are being fostered by the different initiatives carried out by the government and non-governmental organizations.
Market segmentation is done according to end-users, application, region, and product type.
Product type- Albumin, factor VIII concentrate, factor IX concentrate, immunoglobulins, anti-inhibitor coagulation complex.
Application- Bleeding disorders, genetic lung disorders, HIV treatments, hemophilia (A&B), hepatitis (B&C), trauma, burns, cardiopulmonary needs, liver conditions, immune system deficiencies and dysfunctions
End users- Clinics, hospitals, blood transfusion centers, and research institutes
Region- North America Europe, Asia Pacific, and Middle East & Africa in this order. China is a big consumer and manufacturer of these products.
It’s the demand for blood plasma that is driving regional growth and with a population crossing 1.3 billion, which is a lot of end-users and applications. Products can be purchased via two independent blood plasma services – a non-remunerated blood bank system that is fully voluntary and the other commercial plasma collection sources.
Blood collected using the first option goes straight to clinical transfusions in hospitals, while the commercially collected blood is used by fractionation labs to derive plasma.
Whole blood and apheresis platelets collected from the voluntary non-remunerated whole blood banking system are used directly in clinical transfusion, while commercial source plasma is fractionated into plasma-derived products.
Still, all volunteers are paid and the state-owned all of the plasmapheresis centers till 2006, when they were handed over to the plasma fractionation companies. In 1998, the Chinese had implemented this law on blood donations, clinical transfusions, and defines all standards and regulations to be adhered to by these companies.
These two political moves stabilized to blood plasma industry setting the requirements, for blood donations, criteria for selecting ideal donors, quality to be maintained when collecting plasma, storing and transporting it.
Comments